About Novlead
Novlead is a company based in Nanjing (China) founded in 2018. Novlead has raised $18.8 million across 1 funding round from investors including Lilly Asia Ventures, 3E Bioventures Capital and NLVC. Novlead operates in a competitive market with competitors including Aerami, Beyond Air, Breath Therapeutics, Activaero and Pneuma Respiratory, among others.
- Headquarter Nanjing, China
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$18.8 M (USD)
in 1 rounds
-
Latest Funding Round
$18.8 M (USD), Series B
Nov 15, 2021
-
Investors
Lilly Asia Ventures
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Novlead
Unlock access to complete
Funding Insights of Novlead
Novlead has successfully raised a total of $18.8M through 1 strategic funding round. The most recent funding activity was a Series B round of $18.8 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Novlead
Novlead has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly Asia Ventures, 3E Bioventures Capital and NLVC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech & Life Science focused early & growth stage VC firm investing in the US & China
|
Locked | Locked | Locked | |
|
Provider of early stage venture capital focused on technology companies
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Novlead
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novlead
Investment portfolio details for Novlead
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Novlead
Detailed financials for Novlead
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novlead Comparisons
Peer comparison for Novlead
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Novlead
Novlead operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aerami, Beyond Air, Breath Therapeutics, Activaero and Pneuma Respiratory, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for cardiopulmonary diseases are developed using inhaled therapies.
|
|
| Locked | Locked | Locked |
Developer of device for treating respiratory conditions
|
|
| Locked | Locked | Locked |
Inhalation therapies are developed for severe respiratory orphan diseases.
|
|
| Locked | Locked | Locked |
Controlled breathing technologies for inhaler devices were developed.
|
|
| Locked | Locked | Locked |
Pulmonary drug delivery solutions are developed using AI-enabled inhalers.
|
|
| Locked | Locked | Locked |
Respiratory drug delivery devices are developed and manufactured.
|
Detailed competitors of Novlead
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novlead
Complete news archive for Novlead
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novlead
Novlead was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Novlead is headquartered in Nanjing, China. It is registered at Nanjing, Jiangsu, China.
Novlead is a funded company, having raised a total of $18.8M across 1 funding round to date.
Novlead was founded in 2018 in Nanjing, China, where medical devices targeting pulmonary diseases are developed. Operations center on nitric oxide-based technologies, with the flagship product INOwill serving as a portable generator for NO gas in pulmonary hypertension treatment. Additional offerings include the NOVLIZ ureteral tube, NOTA prosthesis filling, and INOcure therapy for diabetic foot conditions, which deliver antibacterial and antithrombotic effects in the healthcare sector.
Novlead's top competitors include Beyond Air, Aerami and Breath Therapeutics.
Novlead has 3 investors. Key investors include Lilly Asia Ventures, 3E Bioventures Capital, and NLVC.